1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Real-time Estimate Cboe BZX  -  05/23 02:05:13 pm EDT
137.80 USD   +1.13%
11:48aPfizer says 3 COVID shots protect children under 5
AQ
10:26aPfizer says 3 shots of COVID-19 vaccine for children under 5 about 80% effective
AQ
08:39aWhat you need to know about the coronavirus right now
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna CEO says data for Omicron-specific shot likely available in March

01/17/2022 | 08:59am EDT

Jan 17 (Reuters) - Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.

"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps," Bancel said at the World Economic Forum's virtual Davos Agenda conference.

Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. (https://reut.rs/3FAeyya)

Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.

"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter."

Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.

Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.

However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.

Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.

"Giving boosters at different times, there is really no evidence that's going to hinder (immune response)."

Fauci said the goal should be to have a booster that induces a response against multiple potential variants. (Reporting by Mrinalika Roy in Bengaluru Editing by Mark Potter)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. 1.50% 138.201 Delayed Quote.-46.35%
ON SEMICONDUCTOR CORPORATION -1.57% 55.545 Delayed Quote.-16.87%
All news about MODERNA, INC.
11:48aPfizer says 3 COVID shots protect children under 5
AQ
10:26aPfizer says 3 shots of COVID-19 vaccine for children under 5 about 80% effective
AQ
08:39aWhat you need to know about the coronavirus right now
RE
07:19aINSIDER SELL : Moderna
MT
05/19EU health regulator backs using AstraZeneca COVID shot as booster
RE
05/18Moderna Seeks Swissmedic Nod For COVID-19 Shot In Children Aged Six Months To Five year..
MT
05/18As COVID cases rise, U.S. health officials mull widening additional booster eligibility
RE
05/18Moderna, International AIDS Vaccine Initiative to Start Volunteer Screening for Phase 1..
MT
05/18Piper Sandler Adjusts Moderna's Price Target to $214 From $348, Reiterates Overweight R..
MT
05/18From storage to transport, hurdles to getting COVID vaccine to N.Koreans
RE
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 22 069 M - -
Net income 2022 11 501 M - -
Net cash 2022 18 081 M - -
P/E ratio 2022 5,01x
Yield 2022 -
Capitalization 54 195 M 54 195 M -
EV / Sales 2022 1,64x
EV / Sales 2023 3,33x
Nbr of Employees 2 700
Free-Float 90,6%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 136,25 $
Average target price 212,69 $
Spread / Average Target 56,1%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567
ALNYLAM PHARMACEUTICALS, INC.-22.00%15 980